AstraZeneca has announced promising findings from a Phase III trial examining a novel liver cancer regimen. The combination of immunotherapies and targeted approaches, including IMFINZI, IMJUDO, lenvatinib, and transarterial chemoembolization (TACE), demonstrated a significant delay in disease progression.

Construction of AstraZeneca’s new plant in Albemarle County is progressing swiftly. Local officials have been briefed on both the expected salaries for newly hired workers and the overall size of the operations, raising anticipation about the region’s economic benefit.

AstraZeneca has unveiled a $2 billion plan to expand its manufacturing presence in Maryland, a move that marks its fourth U.S. commitment this year. The announcement highlights not only the company’s continued growth but also the broader impact such investments can have on America’s biotech landscape.